Palobiofarma
Palobiofarma SL is a Spanish biotech company founded in 2006 by a group of scientists with experience of drug discovery in several pharmaceutical companies.
The vision of Pamplona-based Palobiofarma is to discover the first marketed drug based on a selective adenosine receptor modulator.
In October 2015 the company came to a licensing agreement with Novartis. Under the terms of the agreement Novartis acquired exclusive global rights to develop, manufacture and commercialize Palobiofarma´s adenosine A2A receptor antagonist PBF-509, as it entered Phase I clinical trials in Non-Small Cell Lung Cancer.
Additionally, Novartis has access to several adenosine-related patents from Palobiofarma related to the role of adenosine in immunotherapy.
Latest Palobiofarma News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze